ProMIS Neurosciences Announces First Quarter 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2025
0mins
Source: Globenewswire
PRECISE-AD Trial Progress: ProMIS Neurosciences has completed the first cohort of its PRECISE-AD trial evaluating PMN310 for Alzheimer's disease, with six-month interim results expected in early 2026 and topline results anticipated by the end of 2026.
Financial Overview: The company reported a net loss of $7.3 million for Q1 2025, primarily due to increased clinical trial expenses, while cash reserves decreased from $13.3 million at the end of 2024 to $8.4 million by March 31, 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
